Search details
1.
Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia.
Haematologica
; 107(3): 635-643, 2022 03 01.
Article
in English
| MEDLINE | ID: mdl-33567813
2.
Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology.
Blood
; 129(20): 2771-2781, 2017 05 18.
Article
in English
| MEDLINE | ID: mdl-28331056
3.
A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.
Br J Haematol
; 180(4): 550-562, 2018 02.
Article
in English
| MEDLINE | ID: mdl-29194562
4.
Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian Children.
Cancers (Basel)
; 12(5)2020 May 19.
Article
in English
| MEDLINE | ID: mdl-32438682
5.
Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
Br J Haematol
; 146(3): 292-9, 2009 Aug.
Article
in English
| MEDLINE | ID: mdl-19500099
6.
Improving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual disease.
PLoS One
; 8(10): e76455, 2013.
Article
in English
| MEDLINE | ID: mdl-24146872
7.
Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.
J Mol Diagn
; 11(3): 194-200, 2009 May.
Article
in English
| MEDLINE | ID: mdl-19324994
Results
1 -
7
de 7
1
Next >
>>